Study #2023-1072
An open-label, phase 2b, global multicenter cohort trial to assess the safety and efficacy of Zipalertinib in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with Exon 20 insertion and uncommon/single or compound epidermal growth factor receptor mutations
MD Anderson Study Status
Enrolling
Treatment Agent
TAS6417
Description
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Study phase:
Phase II
Physician name:
Yasir Elamin
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-833-559-2966
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.